Government ❯Regulation

Health Regulation

FDA FDA Approval Consumer Protection Insurance Regulation Tobacco Regulation

FDA Rejects Aldeyra's Reproxalap NDA for Dry Eye Disease Over Efficacy Issues

The decision marks the second rejection of the drug application, with Aldeyra planning a mid-2025 resubmission pending new trial results.

Biden Administration Pushes Final Nicotine Reduction Rule for Cigarettes

FDA Faces Critical Decision on MDMA Therapy for PTSD